Monday, September 8, 1997
Emerging Company Profile
The capability to link genes to specific diseases is a bottleneck that hinders faster drug discovery. Genome sequencing produces catalogs of genetic maps, but it cannot associate genes with disease. Gene inheritance studies that attempt to link genetic regions with disease can take years. And, although gene expression technologies have become very fast, their coverage of expressed genes typically is too incomplete to associate individual genes with disease.
CuraGen has developed a platform that integrates the knowledge of genes, pathways and the mechanisms of drug action so that disease-related, trait-specific genes in animal models and humans can be identified immediately through a comparison of different disease states or an analysis of disease progression.